Apogee Therapeutics, Inc
Price
FilingsNewest: 8-K, Agreement endedSep 3 →InsidersNo open-market buys. 7 insiders sold $169.8M, 78 of 79 sales on a 10b5-1 plan.→HoldersVenrock Adviser 11.3%BlackRock 7.3%HBK Investments L P 3.8%→PeersClosest companies: VRDN, SYRE, JBIO→
From the filings
Figures
- Net income
- −$294.4Mlast 12 months
- Operating cash flow
- −$234.5Mlast 12 months
- Cash and equivalents
- $105.6Mat the last balance sheet
- Shares outstanding
- 75.3M shareson issue